Home › Chronic Lymphocytic Leukemia › Pennsylvania › York
Chronic Lymphocytic Leukemia clinical trials in York, PA
3 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in and around York (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RecruitingPhase 3
- Cancer Care Associates of York, York
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
RecruitingPhase 3
- Cancer Care Associates Of York ( Site 0005), York
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingPhase 2
- Cancer Care Associates Of York, York
Chronic Lymphocytic Leukemia trials in other cities
- Boston, MA31 studies
- Columbus, OH28 studies
- Durham, NC27 studies
- Washington, DC22 studies
- Seattle, WA20 studies
- Rochester, MN19 studies
- New York City, NY18 studies
- Houston, TX17 studies
- Baldwin Park, CA16 studies
- Milwaukee, WI15 studies
- Chicago, IL14 studies
- Cincinnati, OH14 studies
Other studies in York
- Non-Small Cell Lung Cancer15 studies
- Lung Cancer8 studies
- Cancer (all types)8 studies
- Breast Cancer8 studies
- Head and Neck Squamous Cell Carcinoma7 studies
- Ovarian Cancer6 studies
- Prostate Cancer5 studies
- Coronary Artery Disease5 studies
- Colorectal Cancer4 studies
- Endometrial Cancer4 studies
- Triple-Negative Breast Cancer4 studies
- Esophageal Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.